

**Fiscal Year 2012 (FY12) Psychological Health and Traumatic Brain Injury (PH/TBI) Research Program
Reference Table of Award Mechanisms and Submission Requirements**

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|---|--|--|--|
| <p>Consortium to Alleviate PTSD (CAP) Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-12-PHTBI-CAP</p> | <p>All DoD, VA, and other investigators</p> | <ul style="list-style-type: none"> • Intended to support a PTSD-focused Consortium aimed at improving the health and well-being of Service Members and Veterans impacted by PTSD. • Objectives: (1) significantly advance treatment strategies for PTSD including interventions for early, chronic, and latent onset cases and (2) identify and confirm clinically relevant biomarkers as diagnostic and prognostic indicators of PTSD and co-occurring disorders. • Focus Areas: Research activities must be focused on PTSD and common co-occurring psychiatric or medical conditions (detailed list in Program Announcement/ Funding Opportunity). • Studies must focus primarily on the clinical application of biomarker-based research (diagnostic-, prognostic-, and treatment-focused). • Applications must propose a minimum of four (4) studies reflective of the Consortium’s objectives and Focus Areas. | <ul style="list-style-type: none"> • The maximum period of performance is 5 years. • The maximum allowable total costs for the entire period of performance are \$20.336M via the DoD. • Up to an additional \$5M per year for 5 years will be provided by the VA to VA sites, depending upon availability of funds. | <p>Pre-application: October 25, 2012 5:00 p.m. Eastern time (ET)</p> <p>Application: January 4, 2013 11:59 p.m. ET</p> |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|--|---|--|--|
| <p>Chronic Effects of Neurotrauma Consortium (CENC) Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-12-PHTBI-CENC</p> | <p>All DoD, VA and other investigators</p> | <ul style="list-style-type: none"> • Intended to support establishment of a comprehensive understanding of the chronic sequelae associated with neurotrauma, primarily focused on mTBI/concussion. • Objectives: (1) establish the association of the chronic effects of mTBI and common comorbidities, (2) determine whether there is a causative effect of chronic mTBI/concussion on neurodegenerative disease and other comorbidities, (3) identify diagnostic and prognostic indicators of neurodegenerative disease and other comorbidities associated with mTBI/concussion, and (4) develop and advance methods to treat and rehabilitate chronic neurodegenerative disease and comorbid effects of mTBI/concussion. • Focus Areas: The Consortium must also propose activities that include the majority of comorbidities associated with the chronic effects of neurotrauma (examples provided in solicitation). • The research studies must evaluate chronic (defined here as greater than 3 months), anatomic, molecular, and physiological changes related to neurotrauma. • Applications must include an initial set of proposed studies agreed upon by the Consortium participants, which are reflective of the Consortium's Objectives and aligned Focus Areas. | <ul style="list-style-type: none"> • The maximum period of performance is 5 years. • The maximum allowable total costs for the entire period of performance are \$37.175M via the DoD. • Up to an additional \$5M per year for 5 years will be provided by the VA to VA sites, depending upon availability of funds. | <p>Pre-application: October 25, 2012 5:00 p.m. Eastern time (ET)</p> <p>Application: January 4, 2013 11:59 p.m. ET</p> |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|---|---|--|--|
| <p>Traumatic Brain Injury Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-12-PHTBI-TBIRA</p> | <p>Independent investigators at all academic levels (or equivalent)</p> | <ul style="list-style-type: none"> • The intent of this mechanism is to: <ul style="list-style-type: none"> ○ Promote new/innovative ideas that are still in the early stages of development and have the potential to yield highly impactful data and new avenues of investigation to further the field of interest; ○ Advance knowledge regarding the theoretical construct surrounding the TBI Research Area of interest to increase scientific understanding of certain phenomena or behaviors; ○ Propose new paradigms or challenging existing paradigms; and ○ Address the technical feasibility of promising new products, pharmacologic agents, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance, and/or emerging approaches and technologies. • Clinical trials are NOT allowed. • Applications MUST specifically address the following research area: <ul style="list-style-type: none"> ○ Identify and Characterize Mechanisms of Traumatic Brain Injury-related Neurodegenerative Diseases, including chronic traumatic encephalopathy, with emphasis on those mechanisms of injury that may be amenable to targeted therapy approaches, including | <ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable direct costs for the entire period of performance are \$500,000 plus indirect costs for applications with a single PI and \$600,000 plus indirect costs for applications with a Partnering PI. | <p>Pre-application: September 21, 2012 5:00 p.m. Eastern time (ET)</p> <p>Application: November 26, 2012 11:59 p.m. ET</p> |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|------------------------|--------------------|---|----------------|----------------------------|
| | | <p>biomarkers that would identify mechanistic targets of therapeutic approaches.</p> <ul style="list-style-type: none">• Applications that include meaningful and productive collaborations between two investigators are encouraged. | | |